Ad06b58c-bbcd-4688-9763-d2962c0ba07c - samples

ABSTRACT: ABACUS is a single arm phase 2 study that investigated 2 cycles of atezolizumab (1200mg Q3) prior to cystectomy in 95 patients with muscle invasive transitional cell cancer (T2-4N0M0). Pathological complete response (pCR) occurring in ≥20% of patients was the primary endpoint. Biomarker analysis on sequential tissue was a co-primary endpoint. This dataset includes clinical phenotype data.

PROVIDER: EGAD00001006200 | EGA |

REPOSITORIES: EGA